Fiona Simpkins, M.D.

faculty photo
Hilarie L. and Mitchell L. Morgan President's Distinguished Professor in Women's Health
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Pennsylvania Hospital, Philadelphia, PA
Active Staff, Gynecologic Oncology, Department of Ob/Gyn, Chester County Hospital, West Chester, PA
Director of Clinical & Translational Gynecologic Oncology Research, Penn Medicine Health System
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
Temple University School of Medicine, Philadelphia, PA, 1999.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Smith AJB, Alvarez R, Heintz J, Simpkins F, Ko EM.: Disparities in clinical trial participation in ovarian cancer: A real-world analysis. Gynecol Oncol. Page: 175:25-31. doi: 10.1016/j.ygyno.2023.05.066. Aug 2023.

Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Martin L, Simpkins F, Giuntoli R 2nd.: Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. Gynecol Oncol. Page: 177:14-19, Aug 2023.

Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Lewis A, Mamidi S, Medvedev S, Anderton J, Tang J, Ferman B, Coats S, Wilkinson RW, Brown, E, Powell Jr. DJ, Simpkins F.: A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression. Clinical Cancer Research, accepted. Aug 2023.

Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S.: A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol. Page: 18(4):517-530, Jul 2023.

Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F.: [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. Clin Cancer Res Page: 29(8):1515-1527. doi: 10.1158/1078-0432.CCR-22-1602, Apr 2023.

Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F: Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. Clin Cancer Res Page: CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444, Apr 2023.

Nasidous D, Kim SH, Simpkins F: Higher rates of neo-adjuvant chemotherapy use among high-risk patients with advanced stage opithelial ovarian carcinoma in associated with improved outcomes. Society of Gynecologic Oncology Conference, Tampa FL Mar 2023.

Nasioudis D, Gysler S, Latif N, Ko E, Cory L, Giuntoli R, Kim SH, Simpkins, F: : Prevalence of ESR1 gene mutations in gynecologic malignancies with high-estrogen receptor expression. Society of Gynecologic Oncology Annual Meeting, Tampa, FL Mar 2023.

Andriani L, George E, Wu S, Walker P, Xiu J, Holloway J, Herzog T, Thaker P, Korn WM, Auslander N, Jones N, Brown E, Ko EM, Simpkins F: Molecular landscape and clinical outcomes of ARID1A mutant ovarian and endometrial cancers. Poster Presentation. Society of Gynecologic Oncology Annual Meeting, Tampa, FL Mar 2023.

Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Simpkins F, Morgan MA, Giuntoli RL 2nd: Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma. Gynecol Oncol Page: 169:41-46. doi: 10.1016/j.ygyno.2022.10.025, Feb 2023.

back to top
Last updated: 08/30/2023
The Trustees of the University of Pennsylvania